EE9800185A - Komplementaarsed adenoviirusvektorsüsteemid ja rakuliinid - Google Patents

Komplementaarsed adenoviirusvektorsüsteemid ja rakuliinid

Info

Publication number
EE9800185A
EE9800185A EE9800185A EE9800185A EE9800185A EE 9800185 A EE9800185 A EE 9800185A EE 9800185 A EE9800185 A EE 9800185A EE 9800185 A EE9800185 A EE 9800185A EE 9800185 A EE9800185 A EE 9800185A
Authority
EE
Estonia
Prior art keywords
cell lines
adenoviral vector
vector systems
complementary adenoviral
replication deficient
Prior art date
Application number
EE9800185A
Other languages
English (en)
Estonian (et)
Inventor
T. Bruder Joseph
Kovesdi Imre
E. Brough Douglas
L. Mcvey Duncan
Lizonova Alena
Original Assignee
Genvec, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec, Inc. filed Critical Genvec, Inc.
Publication of EE9800185A publication Critical patent/EE9800185A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Design And Manufacture Of Integrated Circuits (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
EE9800185A 1995-12-14 1996-12-12 Komplementaarsed adenoviirusvektorsüsteemid ja rakuliinid EE9800185A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/572,126 US5851806A (en) 1994-06-10 1995-12-14 Complementary adenoviral systems and cell lines
PCT/US1996/019839 WO1997021826A2 (fr) 1995-12-14 1996-12-12 Systemes de vecteurs adenoviraux et de lignees cellulaires complementaires

Publications (1)

Publication Number Publication Date
EE9800185A true EE9800185A (et) 1998-12-15

Family

ID=24286453

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800185A EE9800185A (et) 1995-12-14 1996-12-12 Komplementaarsed adenoviirusvektorsüsteemid ja rakuliinid

Country Status (21)

Country Link
US (1) US5851806A (fr)
EP (1) EP0870049B1 (fr)
JP (2) JP3299761B2 (fr)
AT (1) ATE320503T1 (fr)
AU (1) AU711366B2 (fr)
BG (1) BG62739B1 (fr)
BR (1) BR9612677A (fr)
CA (1) CA2238295C (fr)
CZ (1) CZ182798A3 (fr)
DE (1) DE69635931T2 (fr)
EA (1) EA199800566A1 (fr)
EE (1) EE9800185A (fr)
GE (1) GEP20012559B (fr)
HU (1) HUP9902310A3 (fr)
IL (1) IL124797A0 (fr)
IS (1) IS4762A (fr)
NO (1) NO982687L (fr)
NZ (1) NZ325627A (fr)
PL (1) PL327984A1 (fr)
SK (1) SK78598A3 (fr)
WO (1) WO1997021826A2 (fr)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE336587T1 (de) * 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
EA001616B1 (ru) 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6265212B1 (en) * 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
EP0937150A2 (fr) * 1996-09-25 1999-08-25 Novartis AG Lignees cellulaires d'emballage permettant de faciliter le developpement de vecteurs adenoviraux d'une grande capacite
AU745409B2 (en) * 1997-01-29 2002-03-21 Cornell Research Foundation Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
WO2000012740A2 (fr) 1998-08-28 2000-03-09 Duke University ADENOVIRUS A DELETIONS DANS LES SEQUENCES IVa2, 100K ET/OU DE PROTEINES PRETERMINALES
US6303362B1 (en) 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
CA2371069A1 (fr) * 1999-04-23 2001-02-01 Crucell Holland B.V. Systemes et procedes de transfert d'acide nucleique
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
US6627190B2 (en) * 1999-07-12 2003-09-30 Saint Louis University Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
US6613516B1 (en) * 1999-10-30 2003-09-02 Affymetrix, Inc. Preparation of nucleic acid samples
US6867022B1 (en) * 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
US7653769B2 (en) * 2006-12-14 2010-01-26 International Business Machines Corporation Management of devices connected to infiniband ports
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US6591543B2 (en) * 2000-04-14 2003-07-15 Kenneth P. Sabine Top water lure with highly active propeller
US7445929B2 (en) * 2000-05-26 2008-11-04 Dainippon Sumitomo Pharma Co., Ltd. Recombinant adenovirus vector having a reduced side effect
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
EP1203819A3 (fr) 2000-10-06 2002-08-07 Transgene S.A. Vecteurs anti-inflammatoires
US6573092B1 (en) * 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
WO2003025161A1 (fr) 2001-09-18 2003-03-27 Clontech Laboratories, Inc. Procede de producteur dde vecteurs adenoviraux s'appuyant sur une recombinase specifique d'un site
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US20030087438A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. E1-revertant-free adenoviral composition
US20030158112A1 (en) * 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
JP2005536231A (ja) * 2002-05-08 2005-12-02 イントロン，インコーポレーテッド アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型ｒｎａトランススプライシングの使用
EP1579004B1 (fr) * 2002-10-23 2010-06-16 VIRxSYS Corporation Procedes de criblage destines a identifier des molecules de pre-trans-epissage efficaces
JP2006516027A (ja) * 2002-12-02 2006-06-15 ジェンベク、インコーポレイティッド 眼関連障害の治療用材料および治療方法
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US20050042217A1 (en) * 2003-03-19 2005-02-24 Yan Qi Specific inhibition of allorejection
WO2005012537A2 (fr) * 2003-07-25 2005-02-10 Genvec, Inc. Vaccins a base de vecteurs adenoviraux
DE602004025726D1 (de) * 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
CN101507822B (zh) * 2003-11-24 2012-06-06 坎吉有限公司 皮肤瘢痕形成的减少
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
EP1716165A4 (fr) * 2004-01-23 2008-06-18 Virxsys Corp Expression d'apoliproteine a1 (apoa-1) et variants au moyen de transepissage d'arn induit par complexe d'epissage
US8053232B2 (en) 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
US20070207461A1 (en) * 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
WO2005089811A1 (fr) * 2004-03-12 2005-09-29 Genvec, Inc. Materiaux pour traiter des fuites vasculaires dans l'oeil
AU2005243730B2 (en) 2004-04-12 2010-05-27 Genvec, Inc. Method of using adenoviral vectors to induce an immune response
CA2574802A1 (fr) * 2004-07-20 2006-02-02 Isogenis, Inc. Inhibition specifique d'auto-immunite et maladies associees a des auto-antigenes
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
EP1784493A2 (fr) * 2004-09-01 2007-05-16 The Government of the United States of America as Represented by The Department of Health and Human Services Methode d'utilisation de vecteurs adenoviraux presentant une immunogenicite accrue in vivo(en) adenoviral vectors able to transduce apcs, potential use in immune response generation
DE102004047492B4 (de) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
EP1831365B1 (fr) * 2004-10-08 2013-08-07 VIRxSYS Corporation Utilisation d'un trans-epissage d'arn pour le transfert genique d'anticorps et la production polypeptidique d'anticorps
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
US20060188481A1 (en) * 2005-02-22 2006-08-24 Saitama Medical School Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
CN101163494A (zh) 2005-02-23 2008-04-16 Uab研究基金会 烷基糖苷增强的接种
CA2602944C (fr) * 2005-04-11 2015-08-11 Crucell Holland B.V. Purification de virus faisant appel a une ultrafiltration
US8450055B2 (en) * 2005-08-31 2013-05-28 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
BRPI0615400A2 (pt) * 2005-08-31 2011-05-17 Genvec Inc vacinas para malária baseadas em vetor adenoviral
US9651543B2 (en) 2005-08-31 2017-05-16 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
BRPI0618441B8 (pt) * 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
US20080248060A1 (en) * 2007-01-09 2008-10-09 Genvec, Inc. Adenoviral vector-based malaria vaccines
DE602008004476D1 (de) * 2007-03-09 2011-02-24 Vectorlogics Inc Zellen für adenovirusvektor- und proteinherstellung
US20100263066A1 (en) * 2007-04-30 2010-10-14 Medtronic, Inc Inert dna sequences for efficient viral packaging and methods of use
US20090202492A1 (en) * 2008-01-25 2009-08-13 University Of South Florida Adenovirus vaccine utilizing ikk as adjuvant
WO2010033722A2 (fr) 2008-09-17 2010-03-25 Isogenis, Inc. Construction de vecteurs de délivrance de gènes basés sur un adénovirus complètement délété et ses utilisations
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
JP5393896B2 (ja) 2009-10-15 2014-01-22 クルセル ホランド ベー ヴェー アデノウイルス粒子の精製方法
CA2777116C (fr) 2009-10-15 2020-09-01 Crucell Holland B.V. Procede de purification d'adenovirus a partir de cultures a haute densite cellulaire
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (fr) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccins à base de vecteur adénoviral simien
KR20120139672A (ko) 2009-11-09 2012-12-27 젠벡, 인코포레이티드 원숭이 아데노바이러스 벡터의 증식 방법
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
EP2547362B1 (fr) 2010-03-17 2021-08-25 Cornell University Vaccin adénoviral dissocié contre les drogues toxicomanogènes
KR20130010121A (ko) 2010-03-23 2013-01-25 인트렉손 코포레이션 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도
WO2012021730A2 (fr) 2010-08-11 2012-02-16 Genvec, Inc. Vaccin contre le virus syncytial respiratoire (vsr)
US8771709B2 (en) 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
WO2012083297A2 (fr) 2010-12-17 2012-06-21 Genvec, Inc. Vecteurs adénoviraux avec régions d'hexon modifiées
WO2012088041A1 (fr) 2010-12-20 2012-06-28 Genvec, Inc. Vaccin contre la dengue à base d'un vecteur adénoviral
JP6189754B2 (ja) 2011-03-04 2017-08-30 イントレキソン コーポレーション タンパク質を条件的に発現するベクター
WO2012162428A1 (fr) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Primovaccination-rappel pour infection virale
CN103987726B (zh) 2011-10-05 2017-10-03 金维克有限公司 猴(大猩猩)腺病毒或腺病毒载体及其使用方法
JP6757120B2 (ja) 2011-10-05 2020-09-16 ジェンヴェック エルエルシー アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法
WO2013052859A2 (fr) 2011-10-05 2013-04-11 Genvec, Inc. Vaccin contre le virus respiratoire syncytial à base d'un vecteur adénoviral
US9233153B2 (en) 2011-10-05 2016-01-12 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
WO2013116591A1 (fr) 2012-02-02 2013-08-08 Genvec, Inc. Vaccin contre la malaria à base d'un vecteur adénoviral
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
JP5805908B2 (ja) 2012-03-22 2015-11-10 クルセル ホランド ベー ヴェー Ｒｓｖに対するワクチン
HK1210475A1 (en) 2012-05-29 2016-04-22 Genvec, Inc. Herpes simplex virus vaccine
WO2013181128A1 (fr) 2012-05-29 2013-12-05 Genvec, Inc. Vecteurs adénoviraux de sérotype 28 modifiés
EP2970398B1 (fr) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Protéines f de rsv pré-fusion et leur utilisation
KR102236497B1 (ko) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
JP6013654B2 (ja) 2013-09-19 2016-10-25 クルセル ホランド ベー ヴェー 改良されたアデノウイルス製剤
WO2016037154A1 (fr) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Protéines de l'enveloppe du vih-1 recombinantes et leur utilisation
TWI710635B (zh) * 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
RS58080B1 (sr) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
WO2016103238A1 (fr) 2014-12-24 2016-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines du métapneumovirus f recombinant et leur utilisation
DK3247388T3 (da) 2015-01-20 2025-12-22 Us Health Rekombinant human/bovin parainfluenzavirus 3 (b/hpiv3), der udtrykker et kimærisk rsv/bpiv3 f-protein, og anvendelser deraf
WO2016138160A1 (fr) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes du coronavirus du syndrome respiratoire du moyen-orient, anticorps et leur utilisation
DK3271729T3 (da) 2015-03-18 2020-12-14 Janssen Vaccines & Prevention Bv Analyser til rekombinante ekspressionssystemer
JP6735288B2 (ja) 2015-04-14 2020-08-05 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
JP6470872B2 (ja) 2015-08-20 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１８ワクチン
CA3001050C (fr) 2015-10-06 2023-03-28 Janssen Vaccines & Prevention B.V. Methode de prevention de la deterioration de virus provoquee par une sur face au moyen de cyclodextrines
WO2017139392A1 (fr) 2016-02-08 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines d'enveloppe du vih-1 recombinantes et leur utilisation
US10808011B2 (en) 2016-03-09 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant HIV-1 envelope proteins and their use
IL262108B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
JP7053491B2 (ja) 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用ｈｐｖワクチン組み合わせ
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
RU2745500C2 (ru) 2016-06-20 2021-03-25 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
WO2018011196A1 (fr) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Vaccins contre le hpv
WO2018064523A1 (fr) 2016-09-30 2018-04-05 Genvec, Inc. Adénovecteurs pour l'administration d'un matériel génétique thérapeutique dans des lymphocytes t
WO2018067582A2 (fr) 2016-10-03 2018-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes de peptides de fusion env du vih-1 et leur utilisation
US10960070B2 (en) 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
US11034978B2 (en) 2017-02-09 2021-06-15 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
US11235056B2 (en) 2017-03-24 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of HIV-1 gp120 and their use
EP3634449A4 (fr) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. Vecteurs néoantigéniques alphaviraux
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
WO2019079337A1 (fr) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines d'enveloppe recombinées du vih-1 et leur utilisation
WO2019086450A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adénovirus et ses utilisations
CN111372943B (zh) 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒及其用途
WO2019086461A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Vecteurs d'adénovirus et leurs utilisations
WO2019086466A1 (fr) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adénovirus et utilisations associées
LT3743106T (lt) 2018-01-23 2022-09-26 Janssen Vaccines & Prevention B.V. Gripo viruso vakcinos ir jų panaudojimo būdai
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
KR20250136930A (ko) 2018-03-06 2025-09-16 프레시전 인코포레이티드 사람 파필로마바이러스 백신 및 이의 용도
EP3870703A1 (fr) 2018-10-22 2021-09-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Protéine gp120 de recombinaison à délétion de la boucle v1
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US20220204567A1 (en) 2019-04-25 2022-06-30 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
WO2020229577A1 (fr) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Co-administration d'un vaccin contre la grippe saisonnière et vaccin contre le virus respiratoire syncytial à base d'adénovirus
JP2022532742A (ja) 2019-05-15 2022-07-19 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置
MX2021014525A (es) * 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
CA3152957A1 (fr) 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Vaccins contre le virus de la grippe et leurs utilisations
US20220372515A1 (en) 2019-10-03 2022-11-24 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
KR20220076510A (ko) 2019-10-08 2022-06-08 트러스티스 오브 보스톤 칼리지 다수의 서로 다른 비천연 아미노산을 함유하는 단백질 및 이러한 단백질의 제조 및 사용 방법
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021163365A1 (fr) 2020-02-11 2021-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccin contre le sars-cov-2
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
US11213482B1 (en) 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
US11773391B2 (en) 2020-04-01 2023-10-03 University of Pittsburgh—of the Commonwealth System of Higher Education Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
WO2021209897A1 (fr) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Vaccins à base de psma et de steap1 et leurs utilisations
WO2021222639A2 (fr) 2020-04-29 2021-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines du métapneumovirus humain f recombinant et leur utilisation
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
EP4175664A2 (fr) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Néo-antigènes prostatiques et leurs utilisations
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
WO2022035860A2 (fr) 2020-08-10 2022-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccins à adénovirus de type 4 aptes à la réplication exprimant des protéines d'enveloppe du vih et leur utilisation
WO2022232648A1 (fr) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Complexe de glycoprotéine du virus de lassa stabilisé par préfusion et son utilisation
WO2023015186A1 (fr) 2021-08-03 2023-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccination contre le vih-1 et microbicide samt-247 pour prévenir une infection par le vih-1
WO2023091696A1 (fr) 2021-11-19 2023-05-25 Christiana Care Gene Editing Institute, Inc. Système d'administration d'adénovirus pour le traitement du cancer
US20250197455A1 (en) 2022-03-27 2025-06-19 TThe United States of America, as represented by the Secretary, Department of Health and Human Servi Base-covered hiv-1 envelope ectodomains and their use
WO2023196898A1 (fr) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptides mimétiques de la bêta globine et leur utilisation
EP4338727A1 (fr) 2022-09-14 2024-03-20 Roquette Freres Formulations d'adénovirus
WO2024233783A1 (fr) 2023-05-09 2024-11-14 Cornell University Codage de cassette d'expression pour facteur de croissance endothéliale vasculaire
WO2024249626A1 (fr) 2023-05-30 2024-12-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Trimères en tandem triple de l'enveloppe du vih-1 et leur utilisation
WO2025158316A1 (fr) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Néo-antigènes ovariens et leur utilisation
WO2026030724A1 (fr) 2024-08-01 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccin contre le sars-cov-2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ATE404683T1 (de) * 1992-09-25 2008-08-15 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
DE69333886T2 (de) * 1992-11-18 2006-07-27 Arch Development Corp., Chicago Adenovirus-gelenkter Gen-Transfer zum Herz-und glattem vaskulären Muskel
EP1024198A3 (fr) * 1992-12-03 2002-05-29 Genzyme Corporation Vecteurs pseudo-adenoviraux pour la thérapie génique des hémophilies
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
EP0705344B8 (fr) * 1993-06-24 2006-05-10 Advec Inc. Vecteurs a base d'adenovirus destines a la therapie genique
SK282843B6 (sk) * 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
FR2707664B1 (fr) * 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
LU88429A1 (fr) * 1993-11-23 1995-07-10 Wurth Paul Sa Dispositif de chargement d'un four à cuve
CA2117668C (fr) * 1994-03-09 2005-08-09 Izumu Saito Adenovirus recombinant et son mode de production
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors

Also Published As

Publication number Publication date
WO1997021826A3 (fr) 1997-09-12
IL124797A0 (en) 1999-01-26
PL327984A1 (en) 1999-01-04
JPH11502421A (ja) 1999-03-02
JP2002199894A (ja) 2002-07-16
EA199800566A1 (ru) 1999-02-25
BG102612A (en) 1999-04-30
EP0870049B1 (fr) 2006-03-15
ATE320503T1 (de) 2006-04-15
NZ325627A (en) 2000-01-28
BR9612677A (pt) 1999-07-20
JP3299761B2 (ja) 2002-07-08
AU1417797A (en) 1997-07-03
EP0870049A2 (fr) 1998-10-14
MX9804716A (es) 1998-10-31
WO1997021826A2 (fr) 1997-06-19
BG62739B1 (bg) 2000-06-30
HUP9902310A3 (en) 2001-11-28
CZ182798A3 (cs) 1998-11-11
IS4762A (is) 1998-06-03
SK78598A3 (en) 1998-12-02
DE69635931D1 (de) 2006-05-11
DE69635931T2 (de) 2006-11-30
CA2238295C (fr) 2007-04-03
CA2238295A1 (fr) 1997-06-19
AU711366B2 (en) 1999-10-14
NO982687L (no) 1998-07-13
NO982687D0 (no) 1998-06-11
GEP20012559B (en) 2001-10-25
US5851806A (en) 1998-12-22
HUP9902310A2 (hu) 1999-10-28

Similar Documents

Publication Publication Date Title
EE9800185A (et) Komplementaarsed adenoviirusvektorsüsteemid ja rakuliinid
ZA963434B (en) Gene therapy using replication competent targeted adenoviral vectors.
DE69535178D1 (de) Adenoviren-vektor systeme und zelllinien
DK0667912T3 (da) Defekte adenovirusvektorer og anvendelse heraf i genterapi
MX9800719A (es) Proteinas de transporte y sus usos.
DE69619110D1 (de) Adenovirale vektoren für die gentherapie
EP0623171A4 (fr) Molecules d'arn enzymatiques.
HUT73962A (en) New bacillus thuringiensis strains and their insecticidal proteins
ATE328110T1 (de) Chromogenes medium zum nachweis von staphylococcus aureus
IL181695A0 (en) Methods for cultivating cells and propagating viruses
FI961666A7 (fi) Restenosiksen geeniterapia, jossa käytetään adenovirusvektoria
NO910982L (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
DK1082423T3 (da) Cyclin E2-gener og -proteiner
BR9811748A (pt) Genes microbianos para ß-glucuronidasessecretadas, produtos de gene e seus usos
NO981322D0 (no) Farmasöytiske preparater for bruk ved nukleinsyretransfeksjon, og deres anvendelse
NO974179D0 (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
TR199600902A2 (tr) Hücre transfeksiyonu.
DK0870015T3 (da) Xylanaser, gener, der koder for disse, samt anvendelser deraf
AU2240597A (en) Cardiovascular and thrombus imaging agents, methods and kits
SE9700406D0 (sv) Infästning för sönderdelningsblad
AU1491499A (en) Cloning method by multiple digestion, vectors for implementing same and applications
MX9204348A (es) Vector de adn para la transformacion de celulas de bacillus thuringiensis.
ATE334207T1 (de) Zellzikluskontrollpunkt-spezifische gene
RU96103682A (ru) Последовательность днк, кодирующая энзимы биосинтеза акарбозы